September 2023 in “Cureus” Topical finasteride might be a good alternative for hair loss treatment with fewer side effects, but more research is needed.
January 2024 in “International Journal of Molecular Sciences” Blocking the protein CXCL12 with a specific antibody can increase hair growth in common hair loss conditions.
24 citations,
May 2018 in “Indian Journal of Dermatology, Venereology and Leprology” 17 citations,
January 2020 in “The World Journal of Men's Health” Long-term use of finasteride and dutasteride can cause serious health issues like diabetes and liver problems.
April 2019 in “Journal of the Endocrine Society” Androgens and estrogens are crucial for insulin secretion in males.
June 2021 in “EBioMedicine” The authors maintain that shorter androgen receptor alleles may lead to milder COVID-19 by positively affecting the immune response, not due to changes in testosterone levels or activity.
March 2018 in “Dermatología Argentina” The study found that the average age of women diagnosed with Frontal Fibrosing Alopecia in Argentina is higher than in other countries, but their symptoms are similar.
August 2015 in “Dermatología Argentina” Frontal fibrosing alopecia causes hairline recession and eyebrow loss in postmenopausal women.
13 citations,
October 2007 in “Bioorganic & medicinal chemistry letters” A new compound effectively inhibits human 5α-reductase 1.
90 citations,
May 2017 in “JAMA Internal Medicine” Men over 66 taking medication for prostate enlargement have a higher risk of depression and self-harm, especially in the first 18 months of treatment.
49 citations,
January 2004 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.
8 citations,
June 1995 in “Helvetica Chimica Acta” Compound 15a was effective in inhibiting 5α-reductase.
35 citations,
June 2018 in “Urology” The review suggests younger men taking 1 mg finasteride report more side effects, including sexual, skin, metabolic, and psychological issues.
35 citations,
May 2013 in “Sexual medicine reviews” 5-alpha reductase inhibitors slightly increase the risk of sexual and mood side effects, and breast growth in men.
30 citations,
September 2016 in “BMJ” Taking 5-α reductase inhibitors for prostate enlargement or hair loss does not significantly raise the risk of erectile dysfunction.
20 citations,
October 2018 in “The Journal of Urology” Men taking 5-alpha-reductase inhibitors before or after bladder cancer diagnosis had a lower risk of dying from the disease.
20 citations,
April 2005 in “Current Medicinal Chemistry” New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.
13 citations,
November 2019 in “Scientific reports” Certain drugs change freshwater snail shells to a "banana" shape.
9 citations,
December 2019 in “Clinical genitourinary cancer” Taking 5-Alpha Reductase Inhibitors before bladder removal surgery might make high-grade bladder tumors less aggressive.
7 citations,
May 2013 in “European Urology” 5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
6 citations,
January 2018 in “Pharmacoepidemiology and Drug Safety” Starting 5-alpha reductase inhibitors does not significantly increase the risk of rhabdomyolysis in older men, but is linked to a higher risk of muscle conditions.
4 citations,
December 2019 in “Minerva Urology and Nephrology” 5-alpha reductase inhibitors may reduce bladder cancer recurrence and improve survival.
4 citations,
October 2018 in “International Braz J Urol” Taking 5-alpha reductase inhibitors does not increase the risk of breast cancer in men.
2 citations,
March 2018 in “Current Opinion in Urology” 5-alpha reductase inhibitors can cause sexual, neurologic, endocrine, and cardiovascular side effects, but these are rare and usually stop after ending treatment.
75 citations,
January 2014 in “Korean Journal of Urology” 5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.
46 citations,
March 2001 in “Journal of endocrinological investigation” 5α-reductase inhibitors, like finasteride and dutasteride, effectively treat BPH, male baldness, and hirsutism, with potential for acne and prostate cancer prevention.
33 citations,
June 2015 in “Current Opinion in Endocrinology, Diabetes and Obesity” 5α reductase inhibitors treat hair loss but may cause sexual side effects and risks.
22 citations,
November 2018 in “Breast Cancer Research and Treatment” The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.
17 citations,
August 2011 in “Current Medicinal Chemistry” New treatments for enlarged prostate are being developed, some of which may be more effective than current medications.
11 citations,
December 2018 in “Assay and Drug Development Technologies” Natural herbal compounds might treat certain medical conditions by reducing DHT levels, but more research is needed to confirm their effectiveness and safety.